A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z (NCT06929260) | Clinical Trial Compass
TerminatedPhase 1
A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z
Stopped: The study terminated because the clinical development programme for Ceralasertib has been discontinued.
United Kingdom1 participantsStarted 2025-05-21
Plain-language summary
The study aims to assess the effect of ceralasertib on the pharmacokinetics (PK) of Drug X, Drug Y and Drug Z in participants with advanced solid tumours.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion criteria
. Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of the study intervention and of low potential risk for recurrence.
. Basal cell carcinoma of the skin.
. Curatively treated in situ cancer of the cervix.
. Ductal carcinoma in situ.
. Curatively treated lymphomas (without bone marrow involvement).
. Squamous cell carcinoma of the skin or lentigo maligna that has undergone potentially curative therapy.
. Adequately treated carcinoma in situ without evidence of disease.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Area under plasma concentration-time curve from time 0 to infinity (AUCinf)
Timeframe: From Day 5 to Day 30
2
Area under plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast)